Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter ...

Bio-Rad Laboratories BIO is something of a rarity: a small-cap company with a wide economic moat. The company develops products and solutions for the clinical diagnostics and life sciences industries, ...

BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.

In February 2026, Bio-Rad Laboratories reported fourth-quarter 2025 sales of US$693.2 million and net income of US$720 million, marking a return to profitability after a prior-year loss, alongside ...

Q4 2025 Management View Jonathan DiVincenzo, President & COO, stated that Bio-Rad delivered results within revised guidance ...

Bio-Rad trades at nearly 30 times forward earnings despite recent losses, reflecting expectations for a turnaround as its ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago. These ...

Bio-Rad Laboratories shares fell as the company faces margin pressure related to declining academic research funding. The stock slipped 10.6% to $261.43 Friday. Shares are down 14% over the past 12 ...

Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR (ddPCR) platform. Demand for its quality control and ...

During the quarter, Bio-Rad recognized a substantial change in the fair market value of its investment in Sartorius AG, ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an ...